Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.

Moure CJ, Diplas BH, Chen LH, Yang R, Pirozzi CJ, Wang Z, Spasojevic I, Waitkus MS, He Y, Yan H.

Mol Cancer Res. 2019 Oct;17(10):2042-2050. doi: 10.1158/1541-7786.MCR-19-0309. Epub 2019 Jul 10.

PMID:
31292202
2.

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, Grenier C, Huang Z, Murphy SK, McLendon RE, Friedman HS, Friedman AH, Herndon JE 2nd, Sampson JH, Keir ST, Bigner DD, Yan H, He Y.

Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.

PMID:
31040154
3.

Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe.

Liu Y, Carpenter AB, Pirozzi CJ, Yuan H, Waitkus MS, Zhou Z, Hansen L, Seywald M, Odion R, Greer PK, Hawk T, Chin BB, Vaidyanathan G, Zalutsky MR, Yan H, Vo-Dinh T.

Nanotechnology. 2019 Mar 11;30(27):275101. doi: 10.1088/1361-6528/ab0e9c. [Epub ahead of print]

PMID:
30856613
4.

Improved grading of IDH-mutated astrocytic gliomas.

Pirozzi CJ, Yan H.

Nat Rev Neurol. 2018 Jul;14(7):383-384. doi: 10.1038/s41582-018-0019-6. No abstract available.

PMID:
29855600
5.

Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.

Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojevic I, McLendon RE, Friedman HS, He Y, Bigner DD, Yan H.

Cancer Res. 2018 Jan 1;78(1):36-50. doi: 10.1158/0008-5472.CAN-17-1352. Epub 2017 Nov 2.

6.

Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.

Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, McLendon RE, Bigner DD, He Y, Yan H.

Cancer Res. 2017 Nov 15;77(22):6097-6108. doi: 10.1158/0008-5472.CAN-17-1018. Epub 2017 Sep 22.

7.

Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.

Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, He Y, Yan H.

Mol Cancer Res. 2017 May;15(5):507-520. doi: 10.1158/1541-7786.MCR-16-0485. Epub 2017 Feb 1.

8.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD.

Oncotarget. 2014 Mar 30;5(6):1515-25.

9.

KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.

Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y.

Oncotarget. 2013 Nov;4(11):2144-53.

10.

Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.

Reitman ZJ, Pirozzi CJ, Yan H.

Acta Neuropathol. 2013 Dec;126(6):789-92. doi: 10.1007/s00401-013-1207-5. No abstract available.

11.

The genetic landscape of anaplastic astrocytoma.

Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H.

Oncotarget. 2014 Mar 30;5(6):1452-7.

12.

Releasing the block: setting differentiation free with mutant IDH inhibitors.

Pirozzi CJ, Reitman ZJ, Yan H.

Cancer Cell. 2013 May 13;23(5):570-2. doi: 10.1016/j.ccr.2013.04.024.

13.

Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, Spasojevic I, Bigner DD, He Y, Yan H.

Oncotarget. 2012 Aug;3(8):774-82.

14.

Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

Guo C, Pirozzi CJ, Lopez GY, Yan H.

Curr Opin Neurol. 2011 Dec;24(6):648-52. doi: 10.1097/WCO.0b013e32834cd415. Review.

Supplemental Content

Loading ...
Support Center